Skip to main content

Gillies Hunter's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Mar 20, 2024

Accession no.
0001415889-24-008771
Filed
Mar 20, 2024
Trade date
Mar 18, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $181.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gillies HunterCIK 0001868997Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 18, 2024Common StockMOption exerciseAcquired+4,000$1.74+$6,9607,251Direct
Mar 18, 2024Common StockMOption exerciseAcquired+3,000$2.14+$6,42010,251Direct
Mar 18, 2024Common StockSSaleDisposed−6,387$25.81−$164,848.473,864Direct
Mar 18, 2024Common StockSSaleDisposed−613$26.40−$16,183.23,251Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 18, 2024Common StockMOption exerciseDisposed−4,000$0.00$04,036Direct
Mar 18, 2024Common StockMOption exerciseDisposed−3,000$0.00$098,510Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)